Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/55621
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rao, S. | - |
dc.contributor.author | Cunningham, D. | - |
dc.contributor.author | Price, T. | - |
dc.contributor.author | Hill, M. | - |
dc.contributor.author | Ross, P. | - |
dc.contributor.author | Tebbutt, N. | - |
dc.contributor.author | Norman, A. | - |
dc.contributor.author | Oates, J. | - |
dc.contributor.author | Shellito, P. | - |
dc.date.issued | 2004 | - |
dc.identifier.citation | British Journal of Cancer, 2004; 91(5):839-843 | - |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.issn | 1532-1827 | - |
dc.identifier.uri | http://hdl.handle.net/2440/55621 | - |
dc.description.abstract | This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC). Patients received capecitabine 2500 mg m2 day 1, orally divided in two doses of 1250 mg m-2 in the morning and evening for 14 days every 21 days and MMC 7 mg m-2 (maximum total dose 14 mg) as an intravenous bolus every 6 weeks for a total of four courses. The median age was 70 years (range 24–85) and the majority of patients (86.9%) were of performance status 1/2. The most common metastatic site was liver. In all, 84 patients were assessable for response. The overall response rate was 38% (95% CI: 27.7–49.3) and a further 33.3% of patients achieved stable disease over 12 weeks. There was good symptom resolution ranging from 64 to 86%. Grade 3/4 toxicity was as follows: hand–foot syndrome 19.7%; diarrhoea 10%; neutropenia 2.4%; infection 2.3%. Capecitabine and MMC have shown encouraging activity with a favourable toxicity profile, a convenient administration schedule, and could be considered for patients deemed unsuitable for oxaliplatin and irinotecan combinations. | - |
dc.description.statementofresponsibility | S Rao, D Cunningham, T Price, M E Hill, P J Ross, N Tebbutt, A R Norman, J Oates and P Shellito | - |
dc.language.iso | en | - |
dc.publisher | Nature Publishing Group | - |
dc.rights | © 2004 Cancer Research UK | - |
dc.source.uri | http://dx.doi.org/10.1038/sj.bjc.6602039 | - |
dc.subject | colorectal cancer | - |
dc.subject | advanced | - |
dc.subject | chemotherapy | - |
dc.subject | capecitabine | - |
dc.subject | mitomycin C | - |
dc.title | Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1038/sj.bjc.6602039 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Price, T. [0000-0002-3922-2693] | - |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_55621.pdf | Published version | 101.56 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.